BUZZ-NovaBridge rises as stomach cancer drug combo gets FDA fast-track status

NovaBridge Biosciences

NovaBridge Biosciences

NBP

0.00

** Shares of drug developer NovaBridge NBP.O rise 10.8% to $1.63 premarket

** Co says FDA granted fast-track status to experimental drug givastomig with nivolumab and chemotherapy for advanced gastric cancer

** Gastric cancer is a cancer of the stomach; the combo targets specific tumor markers and helps the immune system attack cancer cells

** Says early-stage study showed durable tumor shrinkage with manageable side effects

** Says it plans late-stage study start in Q4 2026, with detailed mid-stage data due in H2 2026

** Co's givastomig is a bispecific antibody being developed with ABL Bio to target tumors and activate immune cells - NBP

** Fast-track status aims to speed development and review for drugs addressing serious diseases with unmet medical needs

** As of last close, stock down ~63% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.